The largest verified hospitalization pool in the peptide file isn't contamination — it's a multidose vial, a syringe, and a measurement error. FDA's own numbers, and what they do and don't prove.
The largest harm pool in this file is a measuring error
Ask where the verified hospitalizations are in the peptide world and the honest answer is not a research chemical. It is the compounded versions of two approved drugs — semaglutide and tirzepatide — drawn from multidose vials instead of the branded single-dose pens the drugs were designed around.
FDA’s alert of July 26, 2024 describes the mechanism precisely: patients — and in some cases clinicians — mis-measured compounded semaglutide from vials and took multiples of the intended amount. Some required hospitalization, with severe nausea and vomiting, hypoglycemia, pancreatitis, and gallstones among the reported outcomes. The molecule did exactly what the molecule does. The vial format, and the absence of the pen’s guardrails, did the damage.
The counts, with their limits attached
FDA’s page on unapproved GLP-1 drugs (figures checked November 8, 2026) reports, as of May 31, 2026:
- 990 adverse-event reports for compounded semaglutide
- More than 730 adverse-event reports for compounded tirzepatide
A separate analysis of FDA’s adverse-event database through December 2024 (published under the National Academy of Medicine’s auspices, 2025) counted roughly 900 reports and 17 deaths associated with compounded semaglutide and tirzepatide combined.
The limits that must print beside those numbers: adverse-event reports are voluntary and unverified; a report is not a causal finding; and there is no reliable denominator of total compounded users, so no true rate can be computed. FDA itself warns against turning its counts into incidence estimates. What the counts establish is scale of reporting — hundreds of reports, including hospitalizations, attached to a format problem that is mechanically understandable and, in the branded pen, engineered away.
Compounded vs. branded, measured
A peer-reviewed pharmacovigilance study (Expert Opinion on Drug Safety, 2026; PMID 40285721) examined 81,078 GLP-1 adverse-event reports from 2018–2024; 707 involved compounded products. Compounded-product reports carried significantly higher reporting odds for:
- Hospitalization — reporting odds ratio 2.35
- Preparation errors — ROR 48.9
- Contamination — ROR 19.0
- Suicidality — ROR 6.34
Reporting-odds ratios measure reporting patterns, not risk itself — the study’s authors say so, and so do we. But a preparation-error signal at that size is exactly what the vial mechanism predicts.
The label can lie, too
FDA also documents fraudulent compounded GLP-1 products bearing false labels — including labels naming pharmacies that do not exist, and labels naming licensed pharmacies that never made the product. Upstream, FDA’s Import Alert 66-80 covers GLP-1 active ingredients: of 48 ingredient sites the agency evaluated, 21% were noncompliant with manufacturing-quality requirements. And enforcement reaches pharmacies as well as websites: FDA’s warning letter to Empower Pharmacy (September 18, 2026) cited sterility and labeling failures in compounded GLP-1 products. FDA has separately warned that salt forms — semaglutide sodium and semaglutide acetate — are different substances from semaglutide base and have not been shown safe or effective.
Get medical care now if
- Severe or persistent vomiting, or inability to keep fluids down, after a GLP-1 injection.
- Severe abdominal pain — pancreatitis and gallbladder events are in this record.
- Shakiness, sweating, confusion, or other signs of low blood sugar — especially if you also take insulin or other diabetes medication.
- Any suspicion that the amount drawn was larger than intended — say so immediately; it is the single most useful fact you can give the treating team.
If you were harmed, report it to FDA MedWatch. Compounders are not required to report adverse events to FDA — the public record on compounded products is built almost entirely from patients and clinicians who filed.
The bottom line
This is the calibration page for the whole dangers section: the best-documented harm in the peptide file comes from a legal molecule, in a legal-ish channel, defeated by a syringe measurement. It is why this site treats “who hands you the product, and in what format” as a safety question on the same level as “what is the molecule.” See also Retatrutide and Contaminated Products & Forged Lab Reports.
Educational information only — not medical or legal advice. Status as of November 9, 2026. See Our Legal Mandate.